Atomo Diagnostics Secures $3 Million in Investment to Fuel Diagnostic Test Commercialisation and Supply Chain Expansion
Atomo Diagnostics, a leader in innovative diagnostic testing solutions, has announced a significant capital raise, securing binding commitments from a cohort of institutional and sophisticated professional investors. The company will raise $3 million through a share placement, with shares offered at 3.3 cents each. This strategic funding injection is poised to accelerate the commercialisation of Atomo’s proprietary diagnostic tests and bolster the supply chain for its key Pascal cassettes.
The placement price represents a discount of approximately 10% to the 15-day volume-weighted average price of Atomo’s shares. Furthermore, each share subscribed for under the placement will come with one free attaching option. These options are exercisable at 4.5 cents and will expire 2.5 years from the date of issue, offering investors potential upside.
In addition to the institutional placement, Atomo Diagnostics is also launching a share purchase plan (SPP). This initiative aims to raise up to an additional $1 million, providing eligible shareholders with the opportunity to acquire more shares. Under the SPP, shareholders can apply for up to $30,000 worth of new shares, further strengthening the company’s financial position.
John Kelly, Managing Director of Atomo Diagnostics, expressed his satisfaction with the outcome of the placement. “To support anticipated growth in the business, we are pleased to have secured firm commitments from institutional and sophisticated professional investors to raise approximately $3m through the placement and thank them for their support,” he stated.
Strategic Allocation of Funds for Growth
The newly acquired capital will be instrumental in driving Atomo’s strategic objectives. A key focus will be the expanded commercialisation of Atomo’s in-house portfolio of proprietary diagnostic tests. This includes promising tests such as Active Syphilis and Liver Function assays, which are set to reach a wider market.
Beyond its own product pipeline, the funds will also enable a significant scale-up of operations to meet the increasing demand for Pascal cassettes. These specialised cassettes are crucial components for Lumos Diagnostics’ FebriDx test, particularly in the United States market. The anticipated growth in demand is linked to recent regulatory approvals for FebriDx and the expansion of Atomo’s “Atomo inside” customer base, as well as the sales of Atomo’s own diagnostic products.
With the capital raised from the placement and the share purchase plan, combined with Atomo’s pro forma cash reserves of approximately $3.5 million as of December 31, 2025, the company is well-positioned to fund its operations through to early 2028. This extended runway provides a stable foundation for executing its growth strategy.
Unlocking Upside Through Strategic Partnerships
The capital raising initiative coincides with a period of anticipated heightened demand for Pascal cassettes, driven by a pivotal development for Lumos Diagnostics. Lumos recently received a CLIA waiver from the US Food and Drug Administration (FDA) for its flagship point-of-care (POC) respiratory test, FebriDx. This regulatory milestone is expected to dramatically expand the addressable market for FebriDx in the US, with estimates suggesting an increase of around 15 times.
Atomo Diagnostics stands to benefit significantly from this development, as FebriDx has been exclusively commercialised using Atomo’s patented Pascal cassette technology. The Pascal cassette is designed to enhance usability and reliability, even in the hands of untrained users, making it an ideal solution for point-of-care diagnostics.
An existing agreement between Atomo and Lumos, which runs until June 30, 2031, mandates that every FebriDx test sold by Lumos to its US distributor, PHASE Scientific, requires an assembled Pascal cassette from Atomo. Lumos has committed to purchasing specific annual volumes of Pascal cassettes to maintain ongoing exclusivity arrangements for their use with FebriDx. Provisions are in place for a shortfall fee if these agreed-upon annual volumes are not met.
Since the initial agreement with Phase Scientific was signed in July 2025, Atomo has already received orders for Pascal cassettes from Lumos totalling approximately $1.57 million. Excluding any prior IP licensing payments made by Lumos, the current agreement has committed Pascal revenues amounting to US$3.4 million (equivalent to approximately $5.2 million), contingent on FebriDx securing the CLIA waiver. It is important to note that this agreement was established prior to Lumos’s deal with PHASE Scientific, and the anticipated volumes are expected to be considerably larger than the contract’s minimum commitments.
“We are now actively scaling up Pascal operations to support growing demand from Lumos and from other new pipeline customers,” Kelly added. “These customers have recognised the outstanding performance that Pascal has delivered for FebriDx and its proven ability to support valuable CLIA waiver approvals in the US market.” This underscores the strategic importance of the Pascal cassette and Atomo’s role in enabling critical diagnostic advancements.















































